<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899652</url>
  </required_header>
  <id_info>
    <org_study_id>B945</org_study_id>
    <secondary_id>CCG-B945</secondary_id>
    <secondary_id>CDR0000538662</secondary_id>
    <secondary_id>COG-B945</secondary_id>
    <nct_id>NCT00899652</nct_id>
  </id_info>
  <brief_title>DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>The Molecular Epidemiology of de Novo and Treatment Related 11q23 Leukemia in the Young</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the
      laboratory may help doctors learn more about changes that occur in DNA and identify
      biomarkers related to cancer.

      PURPOSE: This laboratory study is looking at DNA in bone marrow and blood samples from young
      patients with acute myeloid leukemia or acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular
           heterogeneity of acute lymphoblastic leukemia or acute myeloid leukemia (AML) in infants
           and monoblastic variants of AML in young patients.

        -  Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular
           heterogeneity of secondary AML in young patients.

        -  Compare secondary AML vs de novo AML at the level of Southern blot, breakpoint sequence,
           and DNA topoisomerase II cleavage sites.

      OUTLINE: This is a multicenter study.

      Bone marrow or blood are collected and analyzed by Southern blot for chromosome 11q23
      breakpoints and translocations. Samples from patients with secondary acute myeloid leukemia
      are also examined for MLL gene rearrangements.

      PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical, morphologic, immunologic, cytogenetic, and molecular characteristics of acute lymphoblastic leukemia and de novo and secondary acute myeloid leukemia (AML)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of secondary AML vs de novo AML at the level of Southern blot, breakpoint sequence, and DNA topoisomerase II cleavage sites</measure>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">149</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <description>Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Southern blotting</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>chromosomal translocation analysis</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene rearrangement analysis</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      marrow, blood, pheresis bag
    </textblock>
  </biospec_descr>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of leukemia meeting 1 of the following criteria:

               -  Acute lymphoblastic leukemia OR acute myeloid leukemia (AML) (&lt; 1 year of age at
                  diagnosis)

               -  M4 OR M5 AML (&lt; 5 years of age at diagnosis)

               -  Secondary leukemia (&lt; 21 years of age at diagnosis)

          -  Bone marrow sample, peripheral blood (WBC &gt; 10,000/mmÂ³ and 20% peripheral blasts), or
             pheresis bag available

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly J. Lange, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolyn A. Felix, MD</last_name>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

